Osteoarthritis in dogs: does an EPA/DHA-enriched diet improve weight-bearing and mobility versus a control diet? — LIKELY

In dogs with osteoarthritis, does an EPA/DHA-enriched diet vs a control diet improve weight-bearing and mobility?

Shelf #514 · gate-verified and displayed under the developer's blinded-trial rule

LIKELY: In dogs with osteoarthritis, foods enriched with fish-oil omega-3 fatty acids (EPA/DHA) improved weight-bearing and mobility versus control foods across four randomised trials from a single research programme. On the objective endpoint, Roush 2010 (38 client-owned dogs, randomised, double-blinded) found the change in mean peak vertical force from day 0 to day 90 was significant for the test-food group (5.6%) but not the control group (0.4%), with improvement in peak vertical force in 82% of test-food dogs versus 38% of control dogs. In the largest owner-assessed trial (Roush 2010, 127 dogs, 18 practices, 6 months), owners reported significantly improved ability to rise from rest and play at 6 weeks and to walk at 12 and 24 weeks on the test food, which contained a 31-fold increase in total omega-3 content and a 34-fold decrease in the omega-6 to omega-3 ratio versus the control food. A dose-titration trial (Fritsch 2010, 177 dogs) found significant improvement over a baseline EPA/DHA food only at roughly 3-fold higher EPA+DHA, not at 2-fold, supporting a dose relationship; and a fourth trial (Fritsch 2010, 131 dogs) found carprofen dosage could be reduced significantly faster on the supplemented diet, an NSAID-sparing signal. Design class (a): randomisation and blinding are established by carded records' own wording (two trials state 'Randomized, double-blinded, controlled clinical trial'; the dose-titration record states owners and veterinarians were blinded). The honest limits: every carded trial comes from one coordinated research programme with shared authorship evaluating complete therapeutic diets, so EPA/DHA cannot be fully separated from the diets' other differences (including the much lower omega-6:omega-3 ratio); owner and investigator scores are subjective in three of the four trials; follow-up is 90 days to 6 months; and effects are modest. That body of consistent randomised evidence, including an objective force-plate endpoint, supports LIKELY, not PROBABLE. Drafted Nov 10, 2026 (VetMed build, topic #514); all figures from the abstract fetched and verified at drafting.

Roush 2010: peak vertical force improved significantly on the fish-oil food (change 5.6% versus 0.4% on control) and 82% of test-food dogs improved versus 38% of control dogs over 90 days

Randomized, double-blinded, controlled clinical trial (record's own wording: 'Randomized, double-blinded, controlled clinical trial'; publication types include Randomized Controlled Trial)

Who: Dogs: 38 client-owned dogs with osteoarthritis examined at 2 university veterinary clinics. Dogs were randomly assigned to a typical commercial food (n = 16) or a test food (n = 22) containing 3.5% fish oil omega-3 fatty acids. On day 0 and days 45 and 90, investigators conducted orthopedic evaluations and force-plate analyses of the most severely affected limb, and owners completed questionnaires characterising their dogs' arthritis signs. Primary objective outcome: change in mean peak vertical force (weight-bearing) between days 90 and 0.

Result: The change in mean peak vertical force between days 90 and 0 was significant for the test-food group (5.6%) but not for the control-food group (0.4%). Improvement in peak vertical force values was evident in 82% of the dogs in the test-food group, compared with 38% of the dogs in the control-food group. In addition, according to investigators' subjective evaluations, dogs fed the test food had significant improvements in lameness and weight bearing on day 90, compared with measurements obtained on day 0. The authors conclude that, at least in the short term, dietary supplementation with fish oil omega-3 fatty acids resulted in an improvement in weight bearing in dogs with osteoarthritis.

Watch out: The smallest of the programme's trials (22 versus 16 dogs) and only 90 days. The force-plate figures are within-group changes tested against baseline (significant on test food, not significant on control); the abstract reports no direct between-group P value for peak vertical force and no absolute force values, so no between-group effect size is carded. The test intervention is a complete food containing 3.5% fish oil omega-3 fatty acids, not an EPA/DHA supplement added to an otherwise identical diet in the abstract's description.

Roush JK, Cross AR, Renberg WC, Dodd CE, Sixby KA, Fritsch DA, Allen TA, Jewell DE, Richardson DC, Leventhal PS, Hahn KA. Evaluation of the effects of dietary supplementation with fish oil omega-3 fatty acids on weight bearing in dogs with osteoarthritis. J Am Vet Med Assoc. 2010;236(1):67-73. PMID: 20043801. Registry ID: none in the record. MeSH: Animals · Biomechanical Phenomena · Dog Diseases/diet therapy*, pathology, physiopathology · Dogs · Double-Blind Method · Fatty Acids, Omega-3/therapeutic use* · Female · Fish Oils/administration & dosage, chemistry · Lameness, Animal/diet therapy*, pathology · Male · Osteoarthritis/diet therapy, pathology, physiopathology, veterinary* · Prospective Studies · Range of Motion, Articular · Treatment Outcome · Weight-Bearing/physiology*

Roush 2010 (multicenter): owners of 127 osteoarthritic dogs on the high-omega-3 food reported significantly better rising and playing at 6 weeks and better walking at 12 and 24 weeks than owners of control dogs

Randomized, double-blinded, controlled clinical trial (record's own wording: 'Randomized, double-blinded, controlled clinical trial'; publication types include Multicenter Study and Randomized Controlled Trial)

Who: Dogs: 127 client-owned dogs with osteoarthritis in 1 or more joints, from 18 privately owned veterinary clinics. Dogs were randomly assigned to be fed for 6 months with a typical commercial food or a test food containing a 31-fold increase in total omega-3 fatty acid content and a 34-fold decrease in the omega-6 to omega-3 ratio, compared with the control food. Owners completed a questionnaire about their dog's arthritic condition, and investigators performed a physical examination and collected samples for a complete blood count and serum biochemical analyses (including fatty acid concentrations) at study onset and at 6, 12 and 24 weeks. Outcomes were owner-assessed arthritic signs, investigator examination, and serum fatty acid concentrations.

Result: Dogs fed the test food had a significantly higher serum concentration of total omega-3 fatty acids and a significantly lower serum concentration of arachidonic acid at 6, 12 and 24 weeks. According to owners, dogs fed the test food had a significantly improved ability to rise from a resting position and play at 6 weeks and improved ability to walk at 12 and 24 weeks, compared with control dogs. The authors conclude ingestion of the test food raised blood concentrations of omega-3 fatty acids and appeared to improve the arthritic condition in pet dogs with osteoarthritis. The abstract reports no percentages or score values for the owner assessments, so none are carded.

Watch out: The clinical outcomes here are owner questionnaire responses — subjective and vulnerable to expectation effects even under blinding — with no objective gait measurement; the only hard measurements are serum fatty acid concentrations, which confirm dietary exposure, not clinical benefit. The test food differed from control in total omega-3 content and in omega-6:omega-3 ratio (and, as a formulated therapeutic diet, potentially in other respects the abstract does not enumerate), so the effect cannot be credited to EPA/DHA alone.

Roush JK, Dodd CE, Fritsch DA, Allen TA, Jewell DE, Schoenherr WD, Richardson DC, Leventhal PS, Hahn KA. Multicenter veterinary practice assessment of the effects of omega-3 fatty acids on osteoarthritis in dogs. J Am Vet Med Assoc. 2010;236(1):59-66. PMID: 20043800. Registry ID: none in the record. MeSH: Animal Nutritional Physiological Phenomena/physiology* · Animals · Dog Diseases/blood, diet therapy*, pathology · Dogs · Dose-Response Relationship, Drug · Double-Blind Method · Fatty Acids, Omega-3/administration & dosage*, blood, therapeutic use · Fatty Acids, Omega-6/administration & dosage, blood · Female · Fish Oils*/administration & dosage, chemistry · Food, Fortified · Male · Osteoarthritis/blood, diet therapy, pathology, veterinary* · Severity of Illness Index · Treatment Outcome

Fritsch 2010: tripling dietary EPA+DHA improved lameness and weight-bearing scores versus a baseline omega-3 food (P = .04 and P = .03) in 177 osteoarthritic dogs; doubling it did not

Prospective, randomized, blinded clinical trial (record's own wording: 'Prospective, randomized clinical trial'; 'Both veterinarians and owners were blinded as to which food the dog received'; publication types include Randomized Controlled Trial)

Who: Dogs: 177 client-owned dogs with stable chronic osteoarthritis of the hip or stifle, in a multicentre clinical setting. Dogs were randomly assigned to the baseline therapeutic food (0.8% eicosapentaenoic acid [EPA] + docosahexaenoic acid [DHA]) or experimental foods containing approximately 2- and 3-fold higher EPA+DHA concentrations. Both veterinarians and owners were blinded as to which food the dog received. On days 0, 21, 45 and 90, serum fatty acid concentrations were measured and veterinarians assessed the severity of 5 clinical signs of osteoarthritis; at day 90 veterinarians also scored overall arthritic condition and progression of arthritis from their clinical signs and an owner interview.

Result: Serum concentrations of EPA and DHA rose in parallel with food concentrations. For 2 of 5 clinical signs (lameness and weight bearing) and for overall arthritic condition and progression of arthritis, there was a significant improvement between the baseline and 3X EPA+DHA foods (P = .04, .03, .001, .0008, respectively) but not between the baseline and the 2X EPA+DHA foods. The authors conclude increasing the amount of fish oil beyond that in the baseline food results in dose-dependent increases in serum EPA and DHA concentrations and modest improvements in the clinical signs of osteoarthritis in pet dogs. The abstract reports no score values, so none are carded.

Watch out: There is no zero-omega-3 control in this trial: every dog ate an EPA/DHA-containing food, so this card supports a dose relationship (3X better than 0.8% baseline; 2X not distinguishable) rather than efficacy versus no omega-3. The significant P values for lameness (.04) and weight bearing (.03) are borderline and come from veterinarian scores on 5 clinical signs, of which only 2 reached significance; the authors themselves call the improvements 'modest'. Group sizes per food are not stated in the abstract.

Fritsch D, Allen TA, Dodd CE, Jewell DE, Sixby KA, Leventhal PS, Hahn KA. Dose-titration effects of fish oil in osteoarthritic dogs. J Vet Intern Med. 2010;24(5):1020-6. PMID: 20707845. Registry ID: none in the record. MeSH: Animal Feed/analysis · Animals · Diet/veterinary · Dog Diseases/drug therapy* · Dogs · Dose-Response Relationship, Drug · Fatty Acids/blood · Female · Fish Oils/administration & dosage*, therapeutic use* · Lameness, Animal/drug therapy · Male · Osteoarthritis/drug therapy, veterinary*

Fritsch 2010 (carprofen): carprofen dosage fell significantly faster over 12 weeks in 131 osteoarthritic dogs fed the fish-oil supplemented diet than in dogs fed a low-omega-3 control diet

Randomized, controlled, multisite clinical trial (record's own wording: 'Randomized, controlled, multisite clinical trial'; publication types include Randomized Controlled Trial; the abstract does not state blinding)

Who: Dogs: 131 client-owned dogs with stable chronic osteoarthritis examined at 33 privately owned veterinary hospitals in the United States. In all dogs, carprofen dosage was standardised over a 3-week period to approximately 4.4 mg/kg/day orally. Dogs were then randomly assigned to a food supplemented with fish oil omega-3 fatty acids or a control food with low omega-3 fatty acid content; at 3, 6, 9 and 12 weeks, investigators decided on increasing or decreasing the carprofen dosage from their assessments of 5 clinical signs and owner assessments of 15 signs. Outcome: trajectory and distribution of carprofen dosage changes over 12 weeks.

Result: Linear regression analysis indicated that over the 12-week study period, carprofen dosage decreased significantly faster among dogs fed the supplemented diet than among dogs fed the control diet. The distribution of changes in carprofen dosage for dogs in the control group was significantly different from the distribution of changes in carprofen dosage for dogs in the test group. The authors conclude that in dogs with chronic osteoarthritis receiving carprofen for signs of pain, feeding a diet supplemented with fish oil omega-3 fatty acids may allow for a reduction in carprofen dosage. The abstract reports no dosage amounts, percentages or P values, so none are carded.

Watch out: An NSAID-sparing endpoint is a proxy: carprofen dose was adjusted by investigators using partly subjective sign assessments, the abstract does not state that assessors were blinded, and no pain, gait or dosage numbers are reported in the abstract — so this card supports the direction of the shelf's claim (less systemic drug needed on the diet) but carries no measurable effect size. All dogs were on carprofen throughout, so it says nothing about the diet as sole therapy.

Fritsch DA, Allen TA, Dodd CE, Jewell DE, Sixby KA, Leventhal PS, Brejda J, Hahn KA. A multicenter study of the effect of dietary supplementation with fish oil omega-3 fatty acids on carprofen dosage in dogs with osteoarthritis. J Am Vet Med Assoc. 2010;236(5):535-9. PMID: 20187817. Registry ID: none in the record. MeSH: Animals · Carbazoles/administration & dosage*, therapeutic use · Dietary Supplements · Dog Diseases/drug therapy* · Dogs · Dose-Response Relationship, Drug · Drug Administration Schedule · Female · Fish Oils/therapeutic use* · Male · Osteoarthritis/drug therapy, veterinary*

Synthesis: EPA/DHA-enriched diets improve weight-bearing and mobility in osteoarthritic dogs across four randomised trials, with a dose relationship and an NSAID-sparing signal — LIKELY, from one research programme

Synthesis

Who: Synthesis of the cards above: Roush 2010 force-plate trial (38 client-owned dogs, 2 university clinics, 90 days), Roush 2010 multicenter owner-assessment trial (127 dogs, 18 practices, 6 months), Fritsch 2010 dose-titration trial (177 dogs, baseline versus 2X versus 3X EPA+DHA foods, 90 days) and Fritsch 2010 carprofen trial (131 dogs, 33 practices, 12 weeks). All four trials evaluated fish-oil omega-3 enriched therapeutic foods against control or lower-dose foods in client-owned dogs with osteoarthritis.

Result: (1) Objective weight-bearing: mean peak vertical force change at 90 days was 5.6% on the test food (significant) versus 0.4% on control (not significant); 82% versus 38% of dogs improved (Roush force-plate). (2) Owner-assessed mobility: significantly better rising and playing at 6 weeks and walking at 12 and 24 weeks on the high-omega-3 food (Roush multicenter). (3) Dose relationship: significant improvement in lameness (P = .04) and weight-bearing (P = .03) scores only at 3X EPA+DHA, not at 2X, versus the 0.8% EPA+DHA baseline food (Fritsch dose-titration). (4) NSAID-sparing: carprofen dosage decreased significantly faster on the supplemented diet over 12 weeks (Fritsch carprofen).

Watch out: One programme, one diet concept: Fritsch, Allen, Dodd, Jewell, Leventhal and Hahn appear across all four trials, and no independent-group replication was carded — that, plus subjective scoring in three of four trials and follow-up of 90 days to 6 months, is why this shelf is LIKELY rather than PROBABLE. The diets are complete therapeutic foods; the claim is for EPA/DHA-enriched diets as tested, not for fish-oil capsules or supplements generally, and not for joint structure modification, which no carded record measures. One-home note: omega-3 records for heart failure and arrhythmia home in Shelf #216 and fatty-acid records for atopic dermatitis home in Shelf #279; none of their records is re-carded here — this shelf's records are osteoarthritis-only.

Synthesis of Roush JK et al. PMID: 20043801; Roush JK et al. PMID: 20043800; Fritsch D et al. PMID: 20707845; Fritsch DA et al. PMID: 20187817. Registry IDs as on the individual cards.

Back to the library index · VetMed home

VetMed is an educational resource, not veterinary advice.